CANDEL THERAPEUTICS, INC. Dilutive Share Adjustment
CANDEL THERAPEUTICS, INC. (CADL) reported Dilutive Share Adjustment of 0 shares for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Income Statement › Earnings Per Share
us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment · last filed 2026-08-13
- CANDEL THERAPEUTICS, INC. weighted average number diluted shares outstanding adjustment for the quarter ending 2026-06-30 was 0.00 shares.
- CANDEL THERAPEUTICS, INC. weighted average number diluted shares outstanding adjustment for the quarter ending 2025-06-30 was 0.00 shares.
- CANDEL THERAPEUTICS, INC. weighted average number diluted shares outstanding adjustment for the quarter ending 2025-03-31 was 2.93M shares.
| Period end | Weighted Average Number Diluted Shares Outstanding Adjustment 3 month | Weighted Average Number Diluted Shares Outstanding Adjustment 6 month |
|---|---|---|
| 2026-06-30 | 0.00 shares 10-Q · filed 2026-08-13 | 0.00 shares 10-Q · filed 2026-08-13 |
| 2025-06-30 | 0.00 shares 10-Q · filed 2026-08-13 | 2.25M shares 10-Q · filed 2026-08-13 |
| 2025-03-31 | 2.93M shares 10-Q · filed 2026-05-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Sana Biotechnology, Inc. (SANA) | United States | $0.886B | -4.92 |
| Attovia Therapeutics, Inc. (ATTO) | United States | $0.828B | |
| Odyssey Therapeutics, Inc. (ODTX) | United States | $0.960B | |
| Solid Biosciences Inc. (SLDB) | United States | $0.802B | -5.07 |
| Cullinan Therapeutics, Inc. (CGEM) | United States | $0.993B | -5.72 |
| Monte Rosa Therapeutics, Inc. (GLUE) | United States | $1.002B | -12.81 |
| 4D Molecular Therapeutics, Inc. (FDMT) | United States | $0.733B | -4.10 |
| MeiraGTx Holdings plc (MGTX) | United States | $1.061B | 16.10 |
| Vor Biopharma Inc. (VOR) | United States | $1.091B | 1.60 |
| Aura Biosciences, Inc. (AURA) | United States | $0.639B | -5.61 |